Tirzepatide
Mounjaro / Zepbound
Dual GLP-1/GIP agonist with exceptional weight loss results in clinical trials.
Key Facts: Tirzepatide
Category
Weight Loss & Metabolic
Evidence
Approved
Availability
Prescription
Protocols
5
Half-Life
~5 days
Routes
subcutaneous
Research Overview & Mechanisms
Dual activation of GLP-1 and GIP receptors, enhancing insulin sensitivity and satiety.
Reported Research Benefits
Available Protocols
Frequently Asked Questions
FAQ
Clinical Evidence
Approved by regulatory agencies (FDA/EMA) with extensive Phase III clinical trial data.
80
studies
60
human
Regulatory Status
Dual-action incretin with landmark SURMOUNT trial data showing up to 22.5% weight loss.
Compare Tirzepatide
Scientific Sources & Further Reading
Explore peer-reviewed research about Tirzepatide:
External links open in new tabs. Always verify information with qualified healthcare providers.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →